Please wait a minute...
J Zhejiang Univ (Med Sci)  2020, Vol. 49 Issue (2): 170-177    DOI: 10.3785/j.issn.1008-9292.2020.02.04
    
Principles and suggestions on biosafety protection of biological specimen preservation during prevalence of COVID-19
ZHANG Xiaoyan(),SUN Wei,SHANG Shiqiang,MAO Jianhua,FU Junfen,SHU Qiang,JIANG Kewen*()
BioBank of Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310051, China
Download: HTML( 46 )   PDF(1070KB)
Export: BibTeX | EndNote (RIS)      

Abstract  

Coronavirus disease 2019 (COVID-19) is a grade B infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In pace with the spreading of the disease, biosafety risk of the biological specimen preservation in biobanks has been significantly increased and biosafety protection during biological specimen preservation become increasingly important. According to the related national rules and the corresponding guidelines of Chinese Medical Association, this paper introduced the etiology about SARS-CoV-2, epidemiology about COVID-19, and the biosafety protection principles of individuals and biological specimen storage places in the process of personal protection, protection of collection, transport, handling, preservation, detection, post-detection disposal and emergencies of biological specimen. Emphasized to carry out a strict biosafety-risk assessment on biological specimen basing on virus load information, infectivity, and sample type (possible contact transmission, aerosol transmission, and fecal oral transmission).



Key wordsCoronavirus disease 2019      Severe acute respiratory syndrome coronavirus 2      Novel coronavirus pneumonia      Biological specimen banks      Safety management      Preservation, biological     
Received: 19 February 2020      Published: 28 February 2020
CLC:  Q-34  
Corresponding Authors: JIANG Kewen     E-mail: 21518309@zju.edu.cn;jiangkw_zju@zju.edu.cn
Cite this article:

ZHANG Xiaoyan, SUN Wei, SHANG Shiqiang, MAO Jianhua, FU Junfen, SHU Qiang, JIANG Kewen. Principles and suggestions on biosafety protection of biological specimen preservation during prevalence of COVID-19. J Zhejiang Univ (Med Sci), 2020, 49(2): 170-177.

URL:

http://www.zjujournals.com/med/10.3785/j.issn.1008-9292.2020.02.04     OR     http://www.zjujournals.com/med/Y2020/V49/I2/170


2019冠状病毒病(COVID-19)疫情期生物样本保藏生物安全防护原则及建议

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染引起的2019冠状病毒病(COVID-19)是乙类传染病。随着COVID-19疫情蔓延,生物样本库样本保藏的生物安全风险增加,其生物安全防护显得越来越重要。根据国家有关规定和中华医学会相关指南,本文基于SARS-CoV-2病原学和COVID-19流行病学资料,提出了生物样本采集、转运、处理、保藏、检测、检测后处置、突发事件等过程中个人和生物样本保藏场所的生物安全防护原则及若干建议。强调依据有无病毒载量信息、传染力大小、标本类型(可能接触传播、气溶胶传播、粪口途径传播)对样本进行严格的生物安全风险评估,以指导疫情期间生物样本保藏、确保生物样本库生物安全。


关键词: 2019冠状病毒病,  严重急性呼吸综合征冠状病毒2,  新型冠状病毒肺炎,  生物标本库,  安全管理,  保存, 生物学 
[1]   全国人民代表大会常务委员会.中华人民共和国传染病防治法[Z/OL].[2020-02-10].http://www.npc.gov.cn/npc/c238/202001/099a493d03774811b058f0f0ece38078.shtml.
The National People's Congress of the People's Republic of China. Law of the People's Republic of China on prevention and control of infectious diseases[Z/OL].[2020-02-10]. http://www.npc.gov.cn/npc/c238/202001/099a493d03774811b058f0f0ece38078.shtml. (in Chinese)
[2]   中华人民共和国国家卫生健康委员会办公厅, 国家中医药管理局办公室.新型冠状病毒感染的肺炎诊疗方案(试行第六版)[A/OL].国卫办医涵[2020] 145号.(2020-02-18)[2020-02-28].http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml.
General Office of National Health Commission of the People's Republic of China, Office of National Administration of Traditional Chinese Medicine. Diagnosis and treatment of novel coronavirus pneumonia (trial version 6)[A/OL]. No.145[2020] of the General Office of the National Health Commission. (2020-02-18)[2020-02-28]. http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml. (in Chinese)
[3]   中华人民共和国国家卫生健康委员会办公厅.新型冠状病毒实验室生物安全指南(第二版)[A/OL].国卫办科教函[2020] 70号.(2020-01-23)[2020-02-28].http://www.nhc.gov.cn/xcs/zhengcwj/202001/0909555408d842a58828611dde2e6a26.shtml.
General Office of National Health Commission of the People's Republic of China. Laboratory biosafety guide of 2019 novel coronavirus (version 2)[A/OL]. No.70[2020] of the General Office of the National Health Commission. (2020-01-23)[2020-02-28]. http://www.nhc.gov.cn/xcs/zhengcwj/202001/0909555408d842a58828611dde2e6a26.shtml. (in Chinese)
[4]   中华人民共和国国家卫生健康委员会办公厅.新型冠状病毒感染的肺炎防控方案(第三版)[A/OL].国卫办疾控函[2020] 80号.(2020-01-28)[2020-02-28].http://www.nhc.gov.cn/jkj/s7923/202001/470b128513fe46f086d79667db9f76a5.shtml.
General Office of National Health Commission of the People's Republic of China. Prevention of pneumonia caused by novel coronavirus (version 3)[A/OL].No.80[2020] of the General Office of the National Health Commission. (2020-01-28)[2020-02-28]. http://www.nhc.gov.cn/jkj/s7923/202001/470b128513fe46f086d79667db9f76a5.shtml. (in Chinese)
[5]   中华人民共和国国家卫生健康委员会办公厅.新型冠状病毒感染的肺炎防控中常见医用防护用品使用范围指引(试行)[A/OL].国卫办医函[2020] 75号.(2020-01-27)[2020-02-28].http://www.nhc.gov.cn/xcs/zhengcwj/202001/e71c5de925a64eafbe1ce790debab5c6.shtml.
General Office of National Health Commission of the People's Republic of China. Guidelines for the use of common medical protective products in the prevention and control of pneumonia due to new coronavirus infection (trial version)[A/OL]. No.75[2020] of the General Office of the National Health Commission. (2020-01-27)[2020-02-28]. http://www.nhc.gov.cn/xcs/zhengcwj/202001/e71c5de925a64eafbe1ce790debab5c6.shtml. (in Chinese)
[6]   中华人民共和国国务院.病原微生物实验室生物安全管理条例[A/OL].国务院令第424号.(2004-11-12)[2020-02-28].http://www.gov.cn/zhengce/content/2008-03/28/content_6264.htm.
State Council of the People's Republic of China. Regulations on biological safety management of pathogenic microbial laboratories[A/OL]. Decree No. 424 of the State Council. (2004-11-12)[2020-02-28]. http://www.gov.cn/zhengce/content/2008-03/28/content_6264.htm. (in Chinese)
[7]   中华医学会检验医学分会.2019新型冠状病毒肺炎临床实验室检测的生物安全防护指南(试行第一版)[A/OL].(2020-01-30)[2020-02-28].http://www.cslm.org.cn/cn/news.asp?id=73.html.
Chinese Society of Laboratory Medicine. Biosafety protection guidelines for clinical laboratory testing of 2019 novel coronavirus pneumonia (trial version 1)[A/OL]. (2020-01-30)[2020-02-28]. http://www.cslm.org.cn/cn/news.asp?id=73.html. (in Chinese)
[8]   中华医学会检验医学分会 . 新型冠状病毒肺炎病毒核酸检测专家共识[J]. 中华医学杂志, 2020, 100 (00): E003- E003-
Chinese Society of Laboratory Medicine . Expert consensus on nucleic acid detection of new coronavirus pneumonia virus[J]. National Medical Journal of China, 2020, 100 (00): E003- E003
doi: 10.3760/cma.j.issn.0376-2491.2020.0003
[9]   Centers for Disease Control and Prevention. Interim guidelines for collecting, handling, and testing clinical specimens from patients under investigation (PUIs) for 2019 novel coronavirus (2019-nCoV)[EB/OL]. (2020-02-02)[2020-02-28]. https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html.
[10]   World Health Organization. Risk communication and community engagement (RCCE) readiness and response to the 2019 novel coronavirus (2019-nCoV) Interim guidance, Interim guidance v2[EB/OL]. (2020-01-26)[2020-02-28]. https://www.who.int/publications-detail/risk-communication-and-community-engagement-readiness-and-initial-response-for-novel-coronaviruses-(-ncov).
[11]   HOLSHUE M L , DEBOLT C , LINDQUIST S et al. First case of 2019 novel coronavirus in the united states[J]. N Engl J Med, 2020, 382 (10):
doi: 10.1056/NEJMoa2001191
[12]   XIA J , TONG J , LIU M et al. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection[J]. J Med Virol, 2020, 1- 6
doi: 10.1002/jmv.25725
[13]   WS/T511-2016经空气传播疾病医院感染预防与控制规范[J].中国感染控制杂志, 2017, 16(5): 490-492. DOI: 10.3969/j.issn.1671-9638.2017.05.023.
WS/T511-2016 Guideline for prevention and control of nosocomial infections through airborne diseases[J]. Chinese Journal of Infection Control, 2017, 16(5): 490-492. DOI: 10.3969/j.issn.1671-9638.2017.05.023.(inChinese)
[14]   中华人民共和国国家质量监督检验检疫总局, 中国国家标准化管理委员会.GB 19258-2012紫外线杀菌灯[S].北京: 中国标准出版社, 2012.
General Administration of Quality Supervision, Inspection and Quarantine of the People's Republic of China, Standardization Administration of China. GB 19258-2012 UV germicidal lamp[S]. Beijing: China Standard Press, 2012. (in Chinese)
[15]   浙江省病原微生物实验室生物安全质量管理中心.生物安全实验室建设与管理[M].杭州: 浙江文艺出版社, 2019.
Pathogen Microbiology Laboratory Biosafety Quality Management Center of Zhejiang Province. Construction and management of biosafety laboratories[M]. Hangzhou: Zhejiang Literature and Art Publishing House, 2019. (in Chinese)
[16]   中华人民共和国卫生部.可感染人类的高致病性病原微生物菌(毒)种或样本运输管理规定[S/OL].中华人民共和国卫生部令(第45号).(2005-12-28)[2020-02-28]. http://www.nhc.gov.cn/qjjys/s3589/200804/081c1f4c9a934fda887c1534abb3dd94.shtml.
Ministry of Health of the People's Republic of China. Regulations on the management of transportation of highly pathogenic pathogenic microorganisms (toxins) or samples that can infect humans[S/OL]. Decree No. 45 of the National Ministry of Health. (2005-12-28)[2020-02-28]. http://www.nhc.gov.cn/qjjys/s3589/200804/081c1f4c9a934fda887c1534abb3dd94.shtml. (in Chinese)
[1] WANG Jincheng,LIU Jinpeng,WANG Yuanyuan,LIU Wei,CHEN Xiaoqun,SUN Chao,SHEN Xiaoyong,WANG Qidong,WU Yaping,LIANG Wenjie,RUAN Lingxiang. Dynamic changes of chest CT imaging in patients with COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 191-197.
[2] CAO Shengli,FENG Peihua,SHI Pengpeng. Study on the epidemic development of COVID-19 in Hubei province by a modified SEIR model[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 178-184.
[3] CHEN Jun,LIU Danping,LIU Li,LIU Ping,XU Qingnian,XIA Lu,LING Yun,HUANG Dan,SONG Shuli,ZHANG Dandan,QIAN Zhiping,LI Tao,SHEN Yinzhong,LU Hongzhou. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 215-219.
[4] CHEN Zhimin,FU Junfen,SHU Qiang,WANG Wei,CHEN Yinghu,HUA Chunzhen,LI Fubang,LIN Ru,TANG Lanfang,WANG Tianlin,WANG Yingshuo,XU Weize,YANG Zihao,YE Sheng,YUAN Tianming,ZHANG Chenmei,ZHANG Yuanyuan. Diagnosis and treatment recommendation for pediatric COVID-19 (the second edition)[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 139-146.
[5] XU Kaijin,CAI Hongliu,SHEN Yihong,NI Qin,CHEN Yu,HU Shaohua,LI Jianping,WANG Huafen,YU Liang,HUANG He,QIU Yunqing,WEI Guoqing,FANG Qiang,ZHOU Jianying,SHENG Jifang,LIANG Tingbo,LI Lanjuan. Management of COVID-19: the Zhejiang experience[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 147-157.
[6] JIANG Saiping,LI Lu,RU Renping,ZHANG Chunhong,RAO Yuefeng,LIN Bin,WANG Rongrong,CHEN Na,WANG Xiaojuan,CAI Hongliu,SHENG Jifang,ZHOU Jianying,LU Xiaoyang,QIU Yunqing. Pharmaceutical care for severe and critically ill patients with COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 158-169.
[7] LI Xin,DAI Tian,WANG Hong,SHI Junnian,YUAN Wei,LI Jing,CHEN Lijun,ZHANG Tianming,ZHANG Shanshan,KONG Yan,YUE Ning,SHI Hui,HE Yuping,HU Huifang,LIU Furong,YANG Caixia. Clinical analysis of suspected COVID-19 patients with anxiety and depression[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 203-208.
[8] LUO Song,YANG Lijuan,WANG Chun,LIU Chuanmiao,LI Dianming. Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 227-231.
[9] HONG Dongsheng,NI Jian,SHAN Wenya,LI Lu,HU Xi,YANG Hongyu,ZHAO Qingwei,ZHANG Xingguo. Establishment of a rapid identification of adverse drug reaction program in R language implementation based on monitoring data[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 253-259.
[10] ZHONG Qi,LI Zhi,SHEN Xiaoyong,XU Kaijin,SHEN Yihong,FANG Qiang,CHEN Feng,LIANG Tingbo. CT imaging features of patients with different clinical types of COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 198-202.
[11] KANG Xianhui,ZHANG Rong,HE Huiliang,YAO Yongxing,ZHENG Yueying,WEN Xiaohong,ZHU Shengmei. Anesthesia management in cesarean section for patient with COVID-19: a case report[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 249-252.
[12] CHEN Xu,LI Yang,WANG Jinxi,CAI Hongliu,CAO Hongcui,SHENG Jifang. Pregnant women complicated with COVID-19: a clinical analysis of 3 cases[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 240-244.
[13] SHEN Lihua,HUANG Fei,CHEN Xiang,XIONG Zuan,YANG Xiaoyu,LI Hui,CHENG Feng,GUO Jian,GONG Guofu. Diagnostic efficacy of three test kits for SARS-CoV-2 nucleic acid detection[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 185-190.
[14] ZHAGN Sheng,LI Danping,CHEN Huazhong,ZHENG Dan,ZHOU Yiping,CHEN Baoguo,SHI Weiwu,LIN Ronghai. Dynamic inflammatory response in a critically ill COVID-19 patient treated with corticosteroids[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 220-226.
[15] LI Youjiang,HU Yingying,ZHANG Xiaodong,YU Yuanyuan,LI Bin,WU Jianguo,WU Yingping,XIA Xiaoping,XU Jian. Follow-up testing of viral nucleic acid in discharged patients with moderate type of COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 270-274.